Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

Abstract Background In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR 0.757) compared with placebo plus fulvestrant in hormone receptor-positive (HR-p...

Full description

Bibliographic Details
Main Authors: Patrick Neven, Hope S. Rugo, Sara M. Tolaney, Hiroji Iwata, Masakazu Toi, Matthew P. Goetz, Peter A. Kaufman, Yi Lu, Nadine Haddad, Karla C. Hurt, George W. Sledge
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Breast Cancer Research
Subjects:
Abemaciclib
Advanced breast cancer
CDK4 and 6 inhibitor
Fulvestrant
Premenopausal women
Online Access:https://doi.org/10.1186/s13058-021-01463-2

Internet

https://doi.org/10.1186/s13058-021-01463-2

Similar Items